Clinical Trials

40 enrolled

Triple Negative Breast Neoplasms

NCT05441098 2022-07-01

Construction and Validation of an Assessment Model of PCR After NAT on Breast Cancer Patients With AI Technology

1,821 enrolled

Pathologic Complete Response, Breast Neoplasms

NCT05343117 2022-04-26

Comparative Effectiveness of PAL Based-therapy as Initial ET Versus PAL Based-therapy After ChT for HR+/HER2- ABC

400 enrolled

Hormone Receptor Positive Advanced Breast Cancer

NCT05291910 2022-03-23

Inetetamab Combined With Anti-PD-1 Monoclonal Antibody and Albumin-Bound Paclitaxel for HER2+ Metastatic Breast Cancer

Phase 4 Unknown

70 enrolled

Breast Neoplasms

NCT05200078 2022-01-20

Deep Inspiration Breath-hold Radiotherapy for Left-sided Breast Cancer

166 enrolled

Breast Neoplasms, Cardiovascular Diseases

NCT05089643 2022-01-10

Anrotinib in Combination With Capecitabine in Advanced Triple Negative Breast Cancer

35 enrolled

Triple Negative Breast Neoplasms

NCT05154396 2021-12-13

Neratinib Dose Escalation Regimen for HER2 Positive Early Breast Cancer

60 enrolled

HER2-positive Breast Cancer

NCT05068115 2021-10-13

Characteristics and Treatment Trends of Young Breast Cancer in China

1,000 enrolled

Breast Neoplasms

NCT05045287 2021-09-16

Hypofractionated Post Mastectomy Radiation With Two-Stage Expander/Implant Reconstruction

Phase NA Unknown

57 enrolled

Breast Neoplasms

NCT05020964 2021-08-25

Screening Plasma HER2 Amplication by Digital PCR in Advanced Breast Cancer Patients Treated With Trastuzumab and Pyrotinib

68 enrolled

Advanced Breast Cancer

NCT04452370 2021-07-21

Oral Etoposide Combined With Anlotinib in Advanced Triple Negative Breast Cancer

Triple Negative Breast Neoplasms

NCT01917279 2020-07-23

CAMELLIA

280 enrolled

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis, Neoplasms by Site, Skin Diseases

NCT03933319 2020-07-08

Phase Ⅱ Study of Pegylated Liposomal Doxorubicin（PLD）Plus Trastuzumab in HER-2 Positive Metastatic Breast Cancer

HER2-positive Breast Cancer

NCT03939871 2020-06-23

A Study of Fluvestrant Combined With Oral Vinorelbine in Hormone Receptor-positive Advanced Breast Cancer

Hormone Receptor Positive Advanced Breast Cancer

NCT04158505 2020-04-24

Real World Study of Pyrotinib in Human Epidermal Growth Factor Receptor-2 (HER2) Positive Breast Cancer

3,000 enrolled

HER2-positive Breast Cancer

NCT04289974 2020-02-28

Predicted Biomarkers of CDK4/6 Inhibitors (Palbociclib) in ER-positive Metastasis Breast Cancer

Breast Neoplasms

NCT04194684 2019-12-11

Nab-Paclitaxel in Patients With ER+/HER2- Recurrent Metastatic Breast Cancer

108 enrolled

Breast Neoplasms

NCT04033172 2019-07-25

Pyrotinib

40 enrolled

Breast Neoplasms

NCT02768415 2019-06-19

Study of Apatinib Combined With Oral Vinorelbine in Metastatic HER2 Negative Breast Cancer

40 enrolled

Breast Neoplasms

NCT03933982 2019-05-29

Pyrotinib

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT03947736 2019-05-14

Dynamic Monitoring of HER2 and ctDNA Specific Mutations in Patients With Recurrent or Metastatic Breast Cancer by Digital PCR

Breast Neoplasms, Recurrence

NCT02765373 2019-05-13

Effects of Adjuvant Endocrine Therapy With Aromatase Inhibitors on the Postoperative Lipid Levels in Postmenopausal Breast Cancer Patients

500 enrolled

Breast Neoplasms

NCT03923166 2019-04-22

Pyrotinib Combined With Capecitabine Metronomic Therapy in HER2-postitive Advanced Breast Cancer

35 enrolled

Breast Neoplasms

NCT03923179 2019-04-22

Phase II Clinical Study of Pyrotinib Combined With Etoposide to Treat HER2-positive Advanced Breast Cancer

32 enrolled

Breast Neoplasms

NCT03876886 2019-03-21

The Trial Comparing Dose-dense AC-T With TP as Adjuvant Therapy for TNBC With Homologous Recombination Repair Deficiency

Triple Negative Breast Neoplasms

NCT03854617 2019-02-26

A Study to Evaluate the Efficacy and Safety of Oral Navelbine in Female Patients With HER2-Negative Metastatic Breast Cancer

172 enrolled

Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

NCT03735082 2018-11-08

Apatinib Combined With Paclitaxel and Carbopatin Intensive Regimen in Neoadjuvant Therapy for Locally Advanced Triple-negative Breast Cancer

29 enrolled

Breast Neoplasms

NCT03047889 2017-02-09

A Nation-wide Multicenter Clinical Epidemiologic Study of Chinese Females With Advanced Breast

4,200 enrolled

Advanced Breast Cancer

NCT02646735 2017-01-02

FRIEND

148 enrolled

Breast Neoplasms

NCT02947061 2016-10-31

S1 Plus Docetaxel Versus Capecitabine Plus Docetaxel First-line Treatment in Patients With Advanced Breast Cancer

300 enrolled

Breast Cancer Recurrent

NCT02934828 2016-10-18

Study of Preoperative Chemotherapy for Early Triple Negative or HER2-positive Operable Breast Cancer

230 enrolled

Breast Neoplasms

NCT02829008 2016-07-12

Low -Dose-bevacizumab and Pemetrexed Versus TPC in Metastatic HER2-negative Breast Cancer Patients

120 enrolled

Breast Neoplasms

NCT02595138 2015-11-03

Zoledronic Acid as Adjuvant Treatment of Triple-negative Breast Cancer

430 enrolled

Triple Negative Breast Neoplasms

NCT01928680 2015-02-23

Phase II Study of Capecitabine and Cisplatin to Treat Metastatic Triple Negative Breast Cancer

33 enrolled 5 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02041338 2014-11-25

Study of Optimizing Neoadjuvant Regimens in Subtypes of Breast Cancer

Breast Neoplasms

NCT01492556 2013-03-15

Study of Etoposide in Treating Patients With Recurrent or Metastatic Breast Cancer

Breast Neoplasms, Neoplasm Metastasis, Recurrence

NCT01431053 2013-03-13

Study of Aspirin and Exemestane as Adjuvant Treatment in Breast Cancer

160 enrolled

Breast Neoplasms

NCT01378533 2011-12-28

The Trial Comparing Dose-dense AC-T With PC as Adjuvant Therapy for TNBC

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01276769 2011-11-16

Comparison Study of Neoadjuvant Paclitaxel Plus Carboplatin/Epirubicin Treatment in Triple-negative Breast Cancer

80 enrolled

Triple Negative Breast Neoplasms

NCT01126138 2011-05-04

Capecitabine (NX) Versus Docetaxel Plus Capecitabine (TX) as 1-line Chemotherapy on Metastatic Breast Cancer (MBC)

Breast Neoplasms, Neoplasm Metastasis, Carcinoma, Ductal, Breast

NCT01278810 2011-01-28

Phase I Study of Novel Estrogen Receptor(ER) a36 Modifier Icaritin in Advanced Breast Cancer Patients

Phase 1 Unknown